Manzo Pharmaceuticals starts human laboratory testing of the company's lactose intolerance probiotic, Lacto-Freedom™
MILFORD, Pa., Oct. 15, 2015 /PRNewswire/ -- Manzo Pharmaceuticals, Inc. (OTCPink:MNZO), today announced that in conjunction with Celprogen, Inc., the human laboratory testing of the company's exciting probiotic, Lacto-Freedom™ has begun. Celprogen has started sending out the test samples of the product marking the start of the much anticipated human testing, which is the last major step before the product can be manufactured and released to the public.
Lacto-Freedom™ is a very exciting probiotic development. In several controlled tests, lactose intolerant laboratory animals, after taking Lacto-Freedom™, showed none of the uncomfortable symptoms associated with lactose intolerance for months after the probiotic was discontinued. Considered a nutritional supplement by the FDA, Lacto-Freedom™ has the potential of eliminating the symptoms of lactose intolerance, a condition that millions of people suffer from every day. Patients suffering from the condition cannot consume any dairy containing products without uncomfortable and sometimes painful repercussions because their digestive tract cannot break down lactase, the sugar contained in dairy products. Lacto-Freedom™ solves the problem by adding lactase digesting bacteria to the intestinal lining, in some cases completely preventing the unpleasant symptoms.
In order to make this breakthrough available to the millions of people whose lives it could change, some human testing is necessary to benchmark the product's success rate, and determine proper dosage and packaging. The company has worked on the details all year and is now finally ready to move forward with Celprogen running the tests. "This is a monumental moment in the company's history. These human tests will position Lacto-Freedom™ to be consumer ready, and our feeling is that it will dramatically change people's lives for the better," commented Manzo Pharmaceuticals' Chief Executive Officer, Kenneth Manzo. "I have waited a long time to get this product out there and this test means we are almost there."
Manzo also has several other products in the works, that the company feels will make an impact in specific markets. Manzo is also preparing to focus on the public equity side of the company, making sure the company is structured in the most efficient way. Part of this is negotiations with debt holders to remove debt from the books and make past fundings that the company inherited less toxic and to protect shareholders from future dilution. The Company plans to build Manzo Pharmaceuticals into a leader in its industry, and to do it the right way every step of the way.
About Manzo Pharmaceuticals, Inc.
Manzo Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the research, development, and testing of patented and non-patented solutions and remedies. Most notably is a patented solution for lactose intolerance, a natural sleep aid, and a natural remedy for colic in babies. For more information follow the company on twitter at @manzopharma, and visit www.manzopharma.com.
DISCLAIMER:
This Press Release may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company has tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential" and similar expressions. These statements reflect the Company's current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance or achievements to differ materially from those expressed in or implied by such statements. The Company undertakes no obligation to update or advise in the event of any change, addition or alteration to the information catered in this Press Release including such forward-looking statements.
SOURCE Manzo Pharmaceuticals, Inc.
Share this article